FDA approves talazoparib with enzalutamide for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with HRR gene mutations

Synopsis

FDA approves talazoparib with enzalutamide for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with HRR gene mutations Refer to the enzalutamide prescribing information for recommended enzalutamide dosing information.

Automatically extracted from the original page. This is a short summary, not the full story, and may omit important detail.